Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies

G Cazzaniga, P de Lorenzo, J Alten, S Röttgers, J Hancock, V Saha, Vincent van der Velden, MG Valsecchi, A Biondi

Research output: Contribution to journalArticleAcademicpeer-review

68 Citations (Scopus)
Original languageUndefined/Unknown
Pages (from-to)107-115
Number of pages9
Issue number1
Publication statusPublished - 2018

Research programs

  • EMC MM-02-72-01

Cite this